Figure 1.
Figure 2.
Figure 3.
Number of death cases, crude rates and ASRs (per 100,000) for pancreatic cancer in Serbia, 2000 – 2021_
| Year | Total | Men | Women | ||||||
|---|---|---|---|---|---|---|---|---|---|
| N | Crude rate | ASRa | N | Crude rate | ASRa | N | Crude rate | ASRa | |
| 2000 | 747 | 9.94 | 5.30 | 401 | 10.97 | 6.48 | 346 | 8.96 | 4.28 |
| 2001 | 772 | 10.29 | 5.34 | 445 | 12.20 | 7.04 | 327 | 8.48 | 3.96 |
| 2002 | 835 | 11.13 | 5.72 | 466 | 12.78 | 7.22 | 369 | 9.58 | 4.49 |
| 2003 | 855 | 11.43 | 5.87 | 451 | 12.40 | 6.98 | 404 | 10.51 | 4.88 |
| 2004 | 852 | 11.42 | 5.70 | 476 | 13.12 | 7.32 | 376 | 9.81 | 4.29 |
| 2005 | 988 | 13.32 | 6.61 | 518 | 14.32 | 8.07 | 470 | 6.25 | 3.11 |
| 2006 | 910 | 12.28 | 6.11 | 520 | 14.43 | 7.99 | 390 | 10.24 | 4.54 |
| 2007 | 966 | 13.09 | 6.18 | 491 | 13.68 | 7.42 | 475 | 12.52 | 5.13 |
| 2008 | 1034 | 14.07 | 6.60 | 561 | 15.70 | 8.29 | 473 | 12.53 | 5.17 |
| 2009 | 1020 | 13.03 | 6.49 | 546 | 15.34 | 8.19 | 474 | 12.60 | 5.01 |
| 2010 | 1088 | 14.92 | 7.06 | 566 | 15.96 | 9.51 | 522 | 13.94 | 5.78 |
| 2011 | 1055 | 14.58 | 6.73 | 570 | 16.18 | 8.32 | 485 | 13.06 | 5.43 |
| 2012 | 1099 | 15.26 | 6.65 | 573 | 16.34 | 8.04 | 526 | 14.24 | 5.46 |
| 2013 | 1070 | 14.93 | 6.56 | 585 | 16.76 | 8.24 | 485 | 13.19 | 5.12 |
| 2014 | 1056 | 14.81 | 6.41 | 573 | 16.50 | 7.99 | 483 | 13.20 | 5.09 |
| 2015 | 1134 | 15.98 | 6.89 | 618 | 17.89 | 8.44 | 516 | 14.18 | 5.61 |
| 2016 | 1151 | 16.31 | 6.83 | 599 | 17.42 | 8.15 | 552 | 15.25 | 5.81 |
| 2017 | 1156 | 16.47 | 6.77 | 619 | 18.10 | 8.35 | 537 | 14.91 | 5.44 |
| 2018 | 1168 | 16.73 | 6.98 | 615 | 18.08 | 8.41 | 553 | 15.44 | 5.79 |
| 2019 | 1206 | 17.36 | 7.14 | 640 | 18.91 | 8.69 | 566 | 15.89 | 5.80 |
| 2020 | 1169 | 16.94 | 6.81 | 625 | 18.60 | 8.46 | 544 | 15.37 | 5.39 |
| 2021 | 1157 | 16.93 | 6.76 | 595 | 17.88 | 7.97 | 562 | 16.02 | 5.74 |
| Overall | 22488 | 14.15 | 6.43 | 12053 | 15.62 | 8.24 | 10435 | 12.55 | 5.06 |
Joinpoint regression analysis* of pancreatic cancer mortality by age in Serbia, 2000 – 2021_
| Total | Men | Women | ||||
|---|---|---|---|---|---|---|
| ASR±SD | AAPCa (95% CIb) | ASR±SD | AAPCa (95% CIb) | ASR±SD | AAPCa (95% CIb) | |
| 25 – 29 | 0.2±0.2 | 0.1±0.2 | 0.2±0.3 | |||
| 30 – 34 | 0.3±0.3 | 0.3±0.4 | 0.3±0.5 | |||
| 35 – 39 | 0.4±0.4 | −0.9 (−4.5–2.9) | 1.2±0.7 | 0.3±0.5 | ||
| 40 – 44 | 2.1±0.6 | −1.3 (−3.6–1.2) | 3.1±1.5 | −1.5 (−4.3–1.5) | 1.4±0.7 | |
| 45 – 49 | 5.01±1.2 | 0.4 (−1.4–2.4) | 6.3±2.0 | −0.5 (−2.5–1.6) | 3.9±1.8 | 2.1 (−2.4–7.1) |
| 50 – 54 | 10.4±1.2 | 0.1 (−0.8–0.9) | 13.8±4.2 | −0.1 (−1.9–1.7) | 7.8±1.5 | 0.5 (−1.2–2.3) |
| 55 – 59 | 18.7±2.1 | 0.1 (−0.8–1.1) | 24.5±3.9 | −0.7 (−1.9–0.5) | 13.3±2.4 | 1.9* (0.6–3.2) |
| 60 – 64 | 27.8±3.0 | 1.2* (0.5–1.8) | 35.2±5.1 | 1.1* (0.1–2.2) | 20.7±4.1 | 1.7 (−0.2–3.7) |
| 65 – 69 | 40.0±5.5 | 1.7* (1.1–2.4) | 50.6±7.4 | 1.* (1.0–2.5) | 30.2±5.8 | 2.1* (0.6–3.7) |
| 70 – 74 | 52.2±6.1 | 1.6* (0.6–2.6) | 63.5±9.8 | 1.6* (0.6–2.6) | 42.9±6.6 | 0.9* (0.01–1.8) |
| 75 – 79 | 62.1±9.4 | 2.5* (1.2–3.7) | 71.3±14.5 | 2.1* (0.6–3.6) | 53.7±9.0 | 2.9* (0.3–3.6) |
| 80 – 84 | 70.4±10.0 | 1.7* (0.7–2.8) | 77.9±18.1 | 1.5 (−1.1–4.3) | 65.2±12.2 | 2.1* (0.7–3.4) |
| 85+ | 63.3±11.4 | 3.1* (1.6–4.5) | 68.2±22.9 | 57.9±13.3 | 4.4* (2.1–6.4) | |